We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-11.31%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$957M
AUM Growth
-$152M
Cap. Flow
+$41.2M
Cap. Flow %
4.3%
Top 10 Hldgs %
58.48%
Holding
65
New
21
Increased
9
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$26.3M
3
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$17.1M
5
ANAB icon
AnaptysBio
ANAB
+$16.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.4M
2
KYNB
Kyntra Bio
KYNB
+$24.3M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$13.4M
4
SAGE
Sage Therapeutics
SAGE
+$12.5M
5
KURA icon
Kura Oncology
KURA
+$8.36M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
51
CytomX Therapeutics
CTMX
$690M
$8K ﹤0.01%
1,101
-408,899
-100% -$2.85M
ARGX icon
52
argenx
ARGX
$55.2B
– –
-202,117
Closed -$32.4M
BMRN icon
53
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-312,500
Closed -$26.4M
EOLS icon
54
Evolus
EOLS
$397M
– –
-600,000
Closed -$7.3M
KYNB
55
CALL
Kyntra Bio
KYNB
$27.4M
– –
-27,060
Closed -$29M
IGMS
56
DELISTED
IGM Biosciences
IGMS
– –
-100,000
Closed -$3.82M
IOVA icon
57
Iovance Biotherapeutics
IOVA
$2.04B
– –
-213,647
Closed -$5.91M
SAGE
58
DELISTED
Sage Therapeutics
SAGE
– –
-173,364
Closed -$12.5M
VCEL icon
59
Vericel Corp
VCEL
$2.38B
– –
-131,001
Closed -$2.28M
XFOR icon
60
X4 Pharmaceuticals
XFOR
$377M
– –
-13,847
Closed -$4.45M
EIGR
61
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-14,978
Closed -$6.7M
HARP
62
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-90,855
Closed -$13.4M
TCRR
63
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-239,500
Closed -$3.42M
RUBY
64
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-525,877
Closed -$5M
UROV
65
DELISTED
Urovant Sciences Ltd.
UROV
– –
-26,468
Closed -$411K
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2020 Portfolio in Review

As of Q1 2020, EcoR1 Capital held 65 positions worth $957M, down 14% from $1.11B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

EcoR1 Capital deployed $41.2M of net new capital in Q1 2020, opening 21 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 2,536,156 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Kyntra Bio, an estimated $24.3M trimmed.

  • EcoR1 Capital's largest Q1 2020 buy was Puma Biotechnology: 2,536,156 shares worth $21.4M.
  • EcoR1 Capital added most to Fate Therapeutics in Q1 2020, an estimated $47.8M increase.
  • EcoR1 Capital's biggest Q1 2020 reduction was Kyntra Bio, cutting an estimated $24.3M.
  • EcoR1 Capital fully exited argenx in Q1 2020, selling an estimated $32.4M.
  • EcoR1 Capital's ten largest holdings make up 58% of its $957M portfolio in Q1 2020.
  • EcoR1 Capital opened 21 new positions and closed 14 in Q1 2020.
  • EcoR1 Capital's portfolio value fell 14% quarter-over-quarter to $957M.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.